3rd Jun 2014 08:12
LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Tuesday that it had launched the first of its two iPad-based products on its Cantab Connect digital platform for use in clinical trials.
Its product, called The Clinical Trials Information System Adverse Effects, allows for the measurement of cognitive impairment in Phase I trials.
Cambridge Cognition said that this allows clients to make early decisions about the cognitive safety of new drugs, which would help reduce the risk of late-stage failures.
The product complies with US Food and Drug Administration guidance that says clinical trial data that includes studies for adverse events such as decreased cognitive function will be given more credence.
Its second iPad based product, CTIS-Abuse Liability, is a patient report system which will help companies comply with FDA guidance calling for drugs that could be abused to be tested for liability.
"As well as significantly reducing errors and the labour-intensity of such work, touch-screen assessment and electronic data capture will accelerate decision making," said Chief Scientific Officer Andy Blackwell in a statement.
Shares in Cambridge Cognition were trading down 5.7% at 58.00 pence Tuesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Cambridge Cog